TrialNet TN22 Hydroxychloroquine Type 1 Diabetes Prevention

• Research type

  Research Study

• Full title

  Hydroxychloroquine for prevention of abnormal glucose tolerance and diabetes in individuals at-risk for type 1 diabetes mellitus.

• IRAS ID

  251667

• Contact name

  Yuk-Fun Liu

• Contact email

  fun.liu@kcl.ac.uk

• Sponsor organisation

  TrialNet Study Group

• Eudract number

  2018-000659-42

• Clinicaltrials.gov Identifier

  NCT03428945

• Clinicaltrials.gov Identifier

  133,873, IND

• Duration of Study in the UK

  6 years, 0 months, 0 days

• Research summary

  This is a double-masked, multicenter, randomised, placebo-controlled trial to determine whether treatment of participants with Stage 1 type 1 diabetes (two or more diabetes-related antibodies with normal glucose tolerance) with hydroxychloroquine results in delay or prevention of progression to Stage 2 type 1 diabetes (abnormal glucose tolerance) or Stage 3 type 1 diabetes (clinical onset).

• REC name

  South West - Central Bristol Research Ethics Committee

• REC reference

  18/SW/0268

• Date of REC Opinion

  11 Jan 2019

• REC opinion

  Further Information Favourable Opinion